Skip to content
Use your HSA or FSA funds

Condition report · Neurological

Tuberous Sclerosis Complex

Whole genome sequencing identifies TSC1 and TSC2 variants, enabling early mTOR inhibitor therapy and organ-specific surveillance tailored to your genetic profile.

A condition report looks for rare variants known to cause the conditions it covers.

Included with every kit

From $449Free shipping · Results in 6–8 weeks

Get my Genome Test

About this condition

Hereditary disease characterized by seizures, intellectual disability, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder affecting approximately 1 in 6,000 to 1 in 10,000 individuals, caused by mutations in TSC1 or TSC2. These genes encode proteins that regulate the mammalian target of rapamycin (mTOR) signaling pathway, a master controller of cell growth. Loss-of-function TSC1 or TSC2 variants cause mTOR hyperactivation, driving excessive cell growth and benign tumor formation throughout the body. TSC manifests as cortical tubers in the brain, subependymal giant cell astrocytomas (SEGAs), angiomyolipomas in the kidneys, skin manifestations (hypomelanotic macules, angiofibromas), and lymphangioleiomyomatosis in the lungs.

Neurological manifestations dominate the TSC disease burden: approximately 80-90% of patients develop epilepsy, often with seizure onset in infancy. Developmental delay and intellectual disability occur variably. Autism spectrum disorder is common. Approximately 33% of TSC cases are de novo mutations. Critically, TSC2 mutations account for approximately 70% of cases and are associated with significantly more severe disease phenotype: earlier seizure onset, higher rates of intellectual disability, and greater tumor burden. TSC1 mutations (~30% of cases) typically produce milder phenotypes with later seizure onset and better cognitive outcomes. Over 1,000 distinct TSC1/TSC2 variants have been identified.

Genotype-phenotype correlation informs surveillance intensity and prognostic counseling. TSC2-positive families should expect more aggressive disease requiring intensive brain and kidney surveillance. A confirmed TSC1 or TSC2 diagnosis mandates comprehensive protocols: brain MRI every 1-3 years to monitor SEGA development (SEGAs cause hydrocephalus and require intervention); renal imaging every 1-3 years for angiomyolipoma and cystic disease assessment; and cardiac echocardiography in infancy. Everolimus (Votubia), an FDA-approved mTOR inhibitor, directly targets the molecular consequence of TSC loss, shrinking SEGAs and angiomyolipomas while improving long-term outcomes. This represents one of the most successful gene-to-drug examples in rare disease.

TSC2 mutations cause more severe disease with earlier seizure onset and higher tumor burden; TSC1 mutations typically produce milder phenotypes with better long-term outcomes.

The condition we analyse

Autosomal dominant

Hereditary disease characterized by seizures, intellectual disability, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.

What a diagnosis changes

mTOR inhibitors, antiepileptic drugs, surveillance imaging, surgical management of complications

Genes analysed

Also known as

adenoma sebaceum; adenoma sebaceum syndrome; Bourneville disease; Bourneville syndrome; Bourneville's disease; Bourneville's syndrome; epiloia; TSC; tuberous sclerosis complex; tuberous sclerosis syndrome

Includes 2 related subtypes ↓
  • tuberous sclerosis 1
  • tuberous sclerosis 2
MONDO:0001734Orphanet 805MedGen 22518

Why whole genome sequencing

TSC1/TSC2 panels are relatively comprehensive but miss large deletions and regulatory variants. De novo detection can be challenging without parental comparison.

Structural variants in TSC1/TSC2 may escape standard panel detection

Although TSC1 and TSC2 are the only genes associated with tuberous sclerosis, standard targeted panels capture most coding sequence but frequently miss large deletions, intronic variants, and regulatory region changes. De novo variant detection can be challenging in sporadic cases if parental samples are not available for comparison. Approximately one-third of TSC cases are de novo, and comprehensive molecular diagnosis in these cases can be elusive with panel-based approaches. Whole genome sequencing provides complete TSC1/TSC2 coverage and enables detection of large structural variants and intronic changes that targeted approaches miss.

Genotype predicts disease severity and guides surveillance intensity

A TSC2 pathogenic variant predicts significantly more aggressive disease: earlier seizure onset, higher rates of intellectual disability, greater tumor burden, and earlier SEGA development requiring mTOR inhibitor intervention. A TSC1 variant typically predicts milder disease with later seizure onset and better cognitive outcomes. This genotype-phenotype correlation directly informs surveillance protocols: TSC2 families require more intensive brain imaging surveillance and lower thresholds for mTOR inhibitor initiation. Everolimus therapy can be started earlier in TSC2 patients to prevent SEGA progression. Cascade family screening identifies first-degree relatives.

Other neurological conditions

All conditions →

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. Physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Free shipping · Results in 6–8 weeks

Get my Genome Test